Tue November 5, 2013
Johnson & Johnson Settles Marketing Charges
Originally published on Tue November 5, 2013 3:08 am
Johnson & Johnson became the latest drugmaker to reach a costly agreement with the federal government over charges of improper marketing. The widely anticipated settlement, unveiled Monday, covers Natrecor, a drug for congestive heart failure, and antipsychotics Risperdal and Invega.